Concall Intelligence
Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search transcript evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.
Management evidence
Generated 21 Oct, 10:30 pm IST · click a summary to inspect source-linked evidence for this results quarter.
| Company | Call and sources | Reported result | Management outlook | Evidence-led conclusion | Review |
|---|---|---|---|---|---|
| ICICIPRULI ICICI Prudential Life Insurance Company Limited Financial Services · Large | Sept 2026 21 Oct 2026 | Good 65/100 | Optimistic outlook Weakened vs prior call No measurable guidance | ICICI Life delivered solid revenue and profit growth despite macro volatility, with strong VNB expansion and margin stability, while emphasizing continued investment in agency distribution and upcoming regulatory reforms. Evidence summary ready | |
| LOTUSDEV Sri Lotus Developers and Realty Limited Real Estate · Micro | Sept 2026 19 Oct 2026 | Excellent 100/100 | Optimistic outlook No comparable prior call New guidance | Sri Lotus delivered strong revenue and profit growth in Q2 FY27, with robust pre‑sales and expanding margins, while management signals confidence in H2 launches and FY27 targets, albeit with execution and pricing risks. Evidence summary ready | |
| HERITGFOOD Heritage Foods Limited FMCG · Micro | Sept 2026 19 Oct 2026 | Bad 0/100 | Cautious outlook Weakened vs prior call No measurable guidance | Heritage Foods posted solid top-line growth but margin pressure from higher milk procurement costs led to a 39.5% YoY decline in PAT, while EBITDA margin improved sequentially. Evidence summary ready | |
| UJJIVANSFB Ujjivan Small Finance Bank Limited Financial Services · Micro | Sept 2026 19 Oct 2026 | Excellent 85/100 | Optimistic outlook No comparable prior call Guidance maintained | Ujjivan Small Finance Bank announced the early retirement of its MD & CEO due to health reasons and appointed Ms. Carol Furtado as Interim MD & CEO. Management reassured stakeholders of continuity in strategy, strong governance, and commitment to FY27 guidance, emphasizing that growth plans and capital adequacy remain unaffected by the leadership transition or potential delays in capital raising. The search for a permanent MD & CEO has been expedited. Evidence summary ready |